Genmab A/S (GMAB)
Nasdaq Copenhagen · Denmark · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 2,997.00 |
|---|---|
| 52-week range | 1,512.00 – 3,060.00 |
| Return, 1 month / 3 months | +31.6% / +57.1% |
| Return, 1 year / 3 years | +60.3% / +49.3% |
| Trend | Uptrend |
| RSI (14) | 84 |
| Volatility (1 year) | 35.5% |
| Worst drawdown (1 year) | -32.3% |
| Average daily value traded | 305.89M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genmab is a biotechnology company based in Copenhagen, Denmark, that develops antibody-based medicines for the treatment of cancer and other serious diseases. Its work centres on creating human antibodies and advancing them through clinical development, often in partnership with larger pharmaceutical companies that handle later-stage development and commercialisation. The company's portfolio includes therapies used in blood cancers and other conditions, and it earns revenue through collaborations, licensing agreements and royalties on products developed from its technology.
On this site Genmab A/S appears as a stock on the Nasdaq Copenhagen (Denmark), code GMAB, with prices in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genmab A/S (GMAB) trades on the Nasdaq Copenhagen in Denmark. It last closed at DKK 2,997.00 on 27 October 2026.
Its price-based Market X-Ray is 79 out of 100 (a strong price profile), ranking 7 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 60.3% and over the last three months it rose 57.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Copenhagen
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 97 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 53.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 57.1% | ||
| 6-month return | 75.6% | ||
| 12-month return, skipping the last month | 21.8% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.3% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 305.89M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +15.2% |
|---|---|
| 1 month | +31.6% |
| 3 months | +57.1% |
| 6 months | +75.6% |
| 1 year | +60.3% |
| 3 years | +49.3% |
| 5 years | +3.2% |
Signals
| 50-day / 200-day average | 2,323.66 / 1,946.76 |
|---|---|
| Golden / death cross (60 days) | Golden, 47 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 96.22 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Copenhagen; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.